U.S. Secures Nearly All Initial Remdesivir Production, But Pays More For It Than Other Developed Countries

By John Wilkerson, Ariel Cohen / June 29, 2020 at 4:29 PM
The Trump administration secured nearly all of Gilead’s initial production of remdesivir but will pay more for it than other developed countries. Gilead set a uniform price for all developed countries, including the United States, that comes out to $2,340 for a five-day course of the antiviral. But the U.S. government didn’t take Gilead up on that offer. Instead, hospitals must buy it on their own at a higher, private-market price, and remdesivir’s list price for hospitals costs $3,120 for...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.